Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - vaistai nuo obstrukcinių kvėpavimo takų ligų, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol, mometasone furoate - astma - vaistai nuo obstrukcinių kvėpavimo takų ligų, - bemrist breezhaler is indicated as a maintenance   treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - vaistai nuo obstrukcinių kvėpavimo takų ligų, - maintenance treatment of asthma in adults whose disease is not adequately controlled.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemija, sirupo ląstelė - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - lipidą keičiančios medžiagos - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinoma, nesmulkiųjų ląstelių skausmas - antinavikiniai vaistai - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited - telbivudinas - hepatitas b, lėtinis - nukleozidų ir nukleotidų atvirkštinės transkriptazės inhibitoriai - sebivo skiriamas gydyti lėtiniu hepatitu b sergantiems kompensuota kepenų liga ir įrodymų, kad virusų replikacija, nuolat padidėjęs alanino aminotransferazės (alt) koncentracija serume ir histologiniu tyrimu patvirtintas aktyvus uždegimas ir (arba) fibrozė. pradžia sebivo gydymas turėtų būti svarstoma tik tada, kai naudojama alternatyvi antivirusinis agentas su didesnės genetinės kliūtis pasipriešinimo nėra, arba atitinkamos.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidų vaizdavimas - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - prostatos navikai, kastracija-atsparus - terapiniai radiofarmaciniai preparatai - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Європейський Союз - литовська - EMA (European Medicines Agency)

novartis europharm limited - ruksolitinibas (fosfatas) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antinavikiniai vaistai - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi fluorouracilu ir folino suaugusių pacientų su polycythaemia vera, kurie yra atsparūs arba netoleruoja hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.